Other Gastrointestinal Diseases

Show Only Open Trials
1.

A Phase 2b, Dose?Ranging, Randomized, Double?Blind, Placebo?Controlled Trial Evaluating the Safety and Efficacy of GS?6624, a Monoclonal Antibody Against Lysyl Oxidase Like 2 (LOXL2) in Subjects with Primary Sclerosing Cholangitis (PSC)

  • Study Status: Open to Enrollment
  • Sponsor: Gilead
  • Disease Status and/or Stage: Primary Sclerosing Cholangitis
  • Protocol ID: WCMC IRB # 1302013540; Gilead GS?US?321?0102
2.

GS-US-321-0105: GS-6624 in the Treatment of Liver Fibrosis in Subjects With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)

  • Study Status: Open to Enrollment
  • Sponsor: Gilead
  • Disease Status and/or Stage: Advanced Liver Fibrosis as a Result of NASH (non-lcoholic steatohepatitis)
3.

GS-US-321-0102: GS-6624 in the Prevention of Progression of Liver Fibrosis in Subjects With With Primary Sclerosing Cholangitis (PSC)

  • Study Status: Open to Enrollment
  • Sponsor: Gilead
  • Disease Status and/or Stage: Primary Sclerosing Cholangtis (PSC)
  • Protocol ID: GS-US-321-0102

Top of page